Remdesivir (Veklury) is authorized by Health Canada to treat patients with severe COVID-19 symptoms who have pneumonia and need extra oxygen to help them breathe. The drug is administered intravenously and is only to be used in health care facilities where patients can be closely monitored.

CADTH recently convened an implementation panel of clinical specialists with experience in the treatment of patients with severe symptoms of COVID-19, as well as an ethicist, to help determine criteria for the use of remdesivir. The panel’s objective was to develop criteria that could help identify which patients would benefit most from treatment with this drug. This work was undertaken to support future pandemic preparedness, where evidence-informed criteria may be useful to support decision-making.

CADTH also completed a Technology Review with a summary and appraisal of the evidence on remdesivir for patients with COVID-19 to inform and help panel members develop these criteria.

Link to Reports:

Drug Implementation Advice: Remdesivir for Severe Symptoms of COVID-19

Remdesivir: Evidence Review and Appraisal

Provide Feedback

Was this site helpful?

If you couldn’t find what you are looking for, please submit a request.